MARTINSRIED / MÜNCHEN, GERMANY--(Marketwire - August 28, 2009) -
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at several upcoming investor conferences.
Sal. Oppenheim European Healthcare Investors Conference Date: Monday, August 31, 2009 Time: 04:10 pm CET (03:10 pm BST, 10:10 am EDT) Venue: Frankfurt/Main, Germany Presenter: Dr. Simon Moroney, CEO of MorphoSys AG Rodman & Renshaw Annual Global Investment Conference Date: Thursday, September 10, 2009 Time: 10:25 am EDT (04:25 pm CET, 03:25 pm BST) Venue: New York, USA Presenter: Dr. Simon Moroney, CEO of MorphoSys AG German Healthcare Conference Organizer: DZ Bank with Deutsche Börse Group Date: Friday, September 11, 2009 Time: 10:45 am CET (04:45 am EDT, 09:45 am BST) Venue: Zurich, Switzerland Presenter: Mr. Dave Lemus, CFO of MorphoSys AG Bank of America Merrill Lynch Global Healthcare Conference Date: Wednesday, September 16, 2009 Time: 11:20 am BST (12:20 pm CET, 06:20 am EDT) Venue: London, UK Presenter: Dr. Simon Moroney, CEO of MorphoSys AG UBS Global Life Sciences Conference Date: Monday, September 21, 2009 Time: 02:30 pm EDT (08:30 pm CET, 07:30 pm BST) Venue: New York, USA Presenter: Dr. Simon Moroney, CEO of MorphoSys AG Commerzbank Life Sciences Forum Date: Thursday, October 1, 2009 Venue: Frankfurt/Main, Germany Presenter: Dr. Simon Moroney, CEO of MorphoSys AG
The PDF versions and, if available, live and archived webcasts of the presentations will be provided at www.morphosys.com.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation, within which it plans to have eight active programs by the end of 2009. Its most advanced program is MOR103, a first-in-class, fully human antibody against GM-CSF. MorphoSys expects to commence a Phase Ib/IIa trial of this antibody in rheumatoid arthritis patients in the second half of 2009. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact MorphoSys: Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 gutjahr-loeser@morphosys.com Mario Brkulj Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 brkulj@morphosys.com Jessica Kulpi Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 kulpi@morphosys.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
